Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LuPARPed: 177Lu-DOTATATE (Lutathera) + olaparib in paediatric SSTR-positive solid tumours
2024-512613-40-00Phase 2Authorised
- Sponsor
- Fundación de Investigación HM Hospitales
- Start
- Aug 2024
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate and olaparib in Nonhematologic neoplasms, sponsored by Fundación de Investigación HM Hospitales. Primary endpoint: Objective tumour response. Planned start Aug 2024; status: authorised.
02
Drugs
lutetium Lu 177 dotatateolaparib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-512613-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512613-40-00.